IP Library Granted Patent US 7,871,632
Granted Patent B2
US 7,871,632 · App. 10/889,226 · Granted Jan 18, 2011

Compositions for delivering highly water soluble drugs

Assignee: Adventrx Pharmaceuticals, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,871,632
App. No.
10/889,226
Granted
Jan 18, 2011
Kind
B2
Abstract

The present invention provides compositions for delivering highly water-soluble drugs (such as vinca alkaloids) and methods of using such compositions.

Claims (18)

1. A composition comprising vinorelbine bitartrate in an oil-in-water emulsion having an oil phase and an aqueous phase, wherein the oil phase comprises a triglyceride oil having medium chain fatty acids, soy lecithin, and oleic acid, and the aqueous phase comprises water, sucrose, and disodium edetate (EDTA) dihydrate, wherein in excess of 80% of the vinorelbine bitartrate is dissolved and remains in the oil phase, and wherein:

(a) vinorelbine bitartrate is at a concentration of 1.4% (w/w);

(b) triglyceride oil having medium chain fatty acids is at a concentration of 15% (w/w);

(c) soy lecithin is at a concentration of 7.5% (w/w);

(d) oleic acid is at a concentration of 1.5% (w/w);

(e) sucrose is at a concentration of 15% (w/w);

(f) disodium edetate (EDTA) dihydrate is at a concentration of 0.005% (w/w);

(g) vinorelbine bitartrate to oleic acid is in a 1:4 molar ratio;

(h) the composition is at a pH of 3.7; and

(i) water is to QS.

2. The composition of claim 1 , wherein the vinorelbine bitartrate in the composition is in a concentration range of 1 to 50 mg/mL.

3. An oil-in-solid dispersion prepared by freeze-drying the composition of claim 1 .

4. The composition of claim 1 , wherein the oil phase of the oil-in-water emulsion comprises oil droplets having an average diameter of less than 200 nm.

5. The composition of claim 4 , wherein the average size of the oil droplets does not increase by about 50% for at least 12 months.

6. The composition of claim 4 , wherein the average size of the oil droplets does not increase by about 50% for at least 24 months.

7. The composition of claim 4 , wherein the composition is stable for at least 12 months.

8. The composition of claim 4 , wherein the composition is stable for at least 24 months.

9. The composition of claim 4 , wherein the composition is filtered through a 0.2 micron-rated membrane filter.

Assignments (4)
CHANGE OF NAME Recorded Mar 21, 2013
From: ADVENTRX PHARMACEUTICALS, INC.
To: MAST THERAPEUTICS, INC.
Reel/Frame 030062/0978 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 25, 2010
From: SD PHARMACEUTICALS, INC.
To: ADVENTRX PHARMACEUTICALS, INC.
Reel/Frame 023840/0096 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 3, 2010
From: SD PHARMEACEUTICALS, INC.
To: ADVENTRX PHARMACEUTICALS, INC.
Reel/Frame 023725/0597 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 25, 2005
From: CHEN, ANDREW XIAN
To: SD PHARMACEUTICALS, INC.
Reel/Frame 015821/0980 →
Continuity (1)
Related Publication 20060008480A1 · Jan 12, 2006